Pfizer CEO Albert Bourla, PhD, pledged that the drugmaker wouldn't be pressured politically to speed up development of its experimental COVID-19 vaccine in an internal memo sent to staff following the Sept. 29 presidential debate, The Hill reported.
Pharmacy
Democrats on the House Oversight Committee pressed executives from Amgen, Novartis and Mallinckrodt to explain price hikes on their drugs in a series of hearings Oct. 1 following the committee's 18-month investigation into the drug industry's pricing practices, STAT reported.
The specialty pharmacy space is evolving quickly, and an increasing number of FDA-approved drugs are specialty drugs. In 2018, 34 percent of FDA-approved drugs were specialty drugs. And although only 2 percent of prescriptions filled in 2018 were specialty drugs,…
Pharmacies have been one of the areas in healthcare hardest hit by the COVID-19 pandemic. They are currently in a state of pseudo-recession, and, according to the National Community Pharmacists Association, two-thirds of pharmacies are experiencing negative cash flow as…
Researchers at the University of Oxford will begin studying AbbVie's drug, Humira, as a potential treatment for COVID-19 patients, the university announced Sept. 30.
Advertisement
The FDA is widening its investigation of AstraZeneca's experimental COVID-19 vaccine, further delaying its U.S. trial that was halted last month after a participant fell ill, Business Insider reported.
With hospitals around the nation facing unprecedented financial burden related to COVID-19, and more people becoming uninsured, it's critical for healthcare leaders to identify sources of revenue and execute cost-saving strategies. Leaders should not overlook pharmacy to help capture savings.
The U.S. government will no longer control distribution of remdesivir, an HHS spokesperson told The Washington Post.
Moderna CEO Stephane Bancel said during a Sept. 30 health conference that the drugmaker's COVID-19 vaccine won't be ready for widespread distribution until spring of 2021, according to CBS News.
Payments to hospitals and physicians — not drug prices — are the main reason the U.S. spends so much more on healthcare than other wealthy countries, despite much of the national conversation around healthcare spending being focused on drug costs, according…